Compare Incyte Corporation (INCY) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Peloton Interactive Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Peloton Interactive Inc trades at $5.43 (market cap $2.46B). The key difference: Incyte Corporation is far larger — about 10× Peloton Interactive Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| INCY | PTON | |
|---|---|---|
Market Cap | $24.54B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $9.00 |
52-Week Low | $81.61 | $3.71 |
Enterprise Value | $20.04B | $2.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Peloton Interactive (PTON) trades at $5.42, down 1.63% today, with a bearish technical signal and negative shareholder equity. The company achieved its first annual net profit in fiscal 2026, with Q4 earnings beating estimates at $0.13 per share. Revenue declined to $2.49 billion in 2025, but net losses narrowed significantly to $119 million. Cash flow turned positive at $335 million, and debt-to-asset ratio improved to 63.18% in 2026. Analyst sentiment is mixed with a 50% buy rating.
Outlook remains cautious due to ongoing revenue declines and high debt, but profitability improvements and cost controls provide a foundation for recovery. Key risks include subscriber losses, competitive pressures, and patent litigation. The stock offers speculative upside if growth stabilizes, but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
